Exhibit
31.1
 
 CERTIFICATION
PURSUANT TO RULE 13a-14 OF THE SECURITIES EXCHANGE ACT OF 1934
 
 I, Dr.
Janet Greeson, certify that:
 
 1.  I
have reviewed this annual report on Form 10-K of Samaritan Pharmaceuticals,
Inc.;
 
 2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact  necessary to make the
statements made, in light of the  circumstances  under which
such statements were made, not misleading with respect to the period covered by
this report;
 
 3.  Based  on
my  knowledge,  the  financial  statements,  and  other
financial information included in this report, fairly present in all material
respects the financial  condition,  results of operations
and cash flows of the registrant as of, and for, the periods presented in this
report;
 
 4.  The  registrant's
other certifying officer and I are responsible for establishing and
maintaining  disclosure  controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal  control
over financial reporting  (as defined in Exchange Act
Rules  13a-15(f) and  15d-15(f),  for the
registrant and have:
 
 a)  Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us
by others within those entities, particularly during
the period in which this report is being prepared;
 
 b)
Designed such internal control over financial reporting, or caused such internal
control
over  financial  reporting  to  be
designed under our supervision, to provide reasonable assurance
regarding the reliability of
financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted
accounting principles;
 
 c)
Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and
 
 d)
Disclosed in this report any change in the registrant's internal control over
financial  reporting that occurred during the registrant's most recent
fiscal  quarter (the  registrant's fourth fiscal
quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the registrant's internal
control over financial reporting; and
 
 5. The
registrant's other certifying officer and I have disclosed,  based on
our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit committee
of registrant's board of directors (or
persons performing the equivalent functions):
 
 a) All
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information; and
 
 b) Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal control over financial
reporting.
  Date:
                June
      17, 2009/s/
      Dr. Janet GreesonDr.
      Janet Greeson
                  Chief
      Executive Officer and President
                  (Principal Executive Officer)